文献速递基础与转化研究临床试验与 GCP

儿童脓毒症生物标志物风险模型(PERSEVERE)的前瞻性临床验证与实验验证

Prospective clinical testing and experimental validation of the Pediatric Sepsis Biomarker Risk Model.
PubMed 文献 · Sci Transl Med · 2019-01-01

该研究在脓毒症队列中验证了PERSEVERE模型对脓毒症患儿死亡风险的预测性能,并在实验性脓毒症小鼠中证实PERSEVERE生物标志物与死亡率的关联,发现被判定为高死亡风险的小鼠细菌负荷更高且可被更高剂量抗生素挽救,危重脓毒症患儿中高病原负荷与高死亡风险的相关性亦得到印证。

要点

  • PERSEVERE在脓毒症患儿队列中展现出优异的死亡风险预测性能。
  • PERSEVERE生物标志物在实验性脓毒症小鼠中与死亡率可靠相关。
  • 基于PERSEVERE富集判定为高死亡风险的小鼠细菌负荷更高,可被更高剂量抗生素挽救。

核心结论

  • PERSEVERE可作为预测性富集策略用于脓毒症精准医学,其引导的床旁到实验再到床旁的转化路径提供了概念验证。

研究设计与样本

  • 研究纳入脓毒症患儿队列前瞻性验证PERSEVERE的预测性能,并在实验性脓毒症小鼠中验证生物标志物与死亡率的关联及基于PERSEVERE富集的治疗策略。

主要发现

  • PERSEVERE在脓毒症患儿队列中展现出优异的死亡风险预测性能。
  • PERSEVERE生物标志物在实验性脓毒症小鼠中与死亡率可靠相关。
  • 被PERSEVERE判定为高死亡风险的小鼠细菌负荷更高,并可被更高剂量抗生素挽救。
  • 危重脓毒症患儿中高病原负荷与高死亡风险的相关性得到印证。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sepsis remains a major public health problem with no major therapeutic advances over the last several decades. The clinical and biological heterogeneity of sepsis have limited success of potential new therapies. Accordingly, there is considerable interest in developing a precision medicine approach to inform more rational development, testing, and targeting of new therapies. We previously developed the Pediatric Sepsis Biomarker Risk Model (PERSEVERE) to estimate mortality risk and proposed its use as a prognostic enrichment tool in sepsis clinical trials; prognostic enrichment selects patients based on mortality risk independent of treatment. Here, we show that PERSEVERE has excellent performance in a diverse cohort of children with septic shock with potential for use as a predictive enrichment strategy; predictive enrichment selects patients based on likely response to treatment. We demonstrate that the PERSEVERE biomarkers are reliably associated with mortality in mice challenged with experimental sepsis, thus providing an opportunity to test precision medicine strategies in the preclinical setting. Using this model, we tested two clinically feasible therapeutic strategies, guided by the PERSEVERE-based enrichment, and found that mice identified as high risk for mortality had a greater bacterial burden and could be rescued by higher doses of antibiotics. The association between higher pathogen burden and higher mortality risk was corroborated among critically ill children with septic shock. This bedside to bench to bedside approach provides proof of principle for PERSEVERE-guided application of precision medicine in sepsis.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Wong HR, Caldwell JT, Cvijanovich NZ, et al. Prospective clinical testing and experimental validation of the Pediatric Sepsis Biomarker Risk Model. Sci Transl Med. 2019. PMID: 31723040. doi:10.1126/scitranslmed.aax9000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。